Groupe d'Etude en Oncologie du Quebec

Titre	Prophylactic Versus Therapeutic Alpha-Blockers in Prostate Cancer Patients Undergoing Radical Course Radiation Therapy ± HDR Boost.
Protocole ID	PCS VII
ClinicalTrials.gov ID	NCT02220829
Type(s) de cancer	Prostate
Phase	Phase III
Institution	CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
Ville	Montréal
Investigateur(trice) principal(e)	Dr Tamim Niazi
Coordonnateur(trice)	Ashley Feng 514-340-8222 poste 26510
Statut	Fermé
Critètes d'éligibilité	Adult male 18 years of age or older Patients with confirmed diagnosis of adenocarcinoma of the prostate. The primary treatment should be external beam radiation therapy (EBRT) with or without high dose rate (HDR) brachytherapy boost. Clinical or radiological diagnosis of T1a - T3b. No limitation with respect to Gleason score. No limitation with respect to total Prostate-specific Antigen (PSA) value. Karnofsky performance score (KPS) of ≥ 70.
Critètes d'exclusion	Small cell cancer of the prostate T4 disease, invading bladder or rectum. Adjuvant or salvage radiation therapy Brachy monotherapy KPS < 70

Groupe d'étude en oncologie du Québec